Median WBC count and platelet values by treatment cohort alone during the collection phase. Panels (A) and (B) show the peripheral WBC count and platelet counts during the collection phase of the study for each treatment cohort. Cytokines (Filgrastim or various doses r-metHuSCF in combination with Filgrastim) were administered on days 1 through 7 for all patients. The dose of Filgrastim was 10 μg/kg/d for all patients. The dose of r-metHuSCF (0 to 20 μg/kg/d) is identified by cohort in the legend. The number of patients in each group are also listed in the legend.